克罗恩病和溃疡性结肠炎的饮食疗法和肠道微生物组
The study is proposed as a 2-year single site, open-label clinical trial of enteral nutrition or the specific carbohydrate diet in patients with active CD or UC. Patients seeking care in the outpatient clinics of the Division of Gastroenterology at Massachusetts General Hospital will be approached for participation in the trial during their routine outpatient appointments. All patients are required to have a diagnosis of CD or UC confirmed using standard clinical, endoscopic, and histologic criteria. Eligible patients will complete an office visit to confirm eligibility for the study and informed consent will be obtained. They will then be scheduled for a routine colonoscopy as part of their standard clinical care to objectively confirm active disease and obtain biopsies for microbiome and gene expression. The investigators will obtain prior authorization from the subject's insurance company for such colonoscopy, or if it is not covered by the insurance, the investigators will use study funds to pay for the procedure. They will then be assigned to one of two dietary intervention arms based on their preference and will meet with the study registered dietician at the MGH Clinical Research Center (CRC) metabolism and nutrition unit. There, they will receive instruction on the components of the assigned dietary therapy arm - partial elemental diet (enteral nutrition) or specific carbohydrate diet, and will complete a baseline food record (FR). They will adhere to the dietary therapy for 6 weeks after which they can resume normal diet. Clinical, biochemical, nutritional, and microbiological parameters will be measured during and for 6 weeks following the study. They will have 5 study visits during this time.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- At least 18 years of age
- Able to provide written informed consent prior to screening and to comply with the requirements of the study protocol.
- Established diagnosis of small bowel or colonic CD or ulcerative colitis
- Confirmation of active CD or UC with recent (within 1 month) objective evidence of active disease on colonoscopy
- Any medications being currently used for IBD must remain stable during the study period with the exception of tapering of corticosteroids.
- Current disease activity defined as a Harvey Bradshaw index > 4 at baseline (week 0) or SCCAI > 3
Exclusion Criteria:
- If female, is pregnant or is breast feeding
- Known celiac disease or subjects with a positive screen for celiac disease (elevated tissue transglutaminase antibodies)
- Inability to provide informed consent or unwilling to participate
- Evidence of untreated infection e.g. clostridium difficile
- Presence of stoma or J pouch
- Presence of enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period
- Bowel surgery within 12 weeks prior to screen and/or has surgery planned or deemed likely for IBD during the study period
- Fixed symptomatic stenosis of small bowel or colon
- Chronic use of narcotics for chronic pain defined as a daily use of one or more doses of narcotic containing medication
- Use of oral or intravenous antibiotics within 4 weeks prior to screening
- Use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Specific carbohydrate arm
The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient. |
|
|
有源比较器:Elemental diet arm
The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical remission
大体时间:Week 6
|
Harvey Bradshaw index < 4 or SCCAI < 3 at week 6 |
Week 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical response
大体时间:Week 6
|
reduction in HBI by 3 or more or SCCAI by 2 or more |
Week 6
|
|
Biochemical response - CRP
大体时间:Week 6
|
Change in serum C-reactive protein from baseline |
Week 6
|
|
Biochemical response - fecal calprotectin
大体时间:Week 6
|
Change in fecal calprotectin from baseline |
Week 6
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in gut microbiome
大体时间:Week 6 and Week 12
|
Change in fecal microbiome pattern assessed using 16sRNA sequencing and shotgun metagenomic sequencing |
Week 6 and Week 12
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.